Metabolic Syndrome Global Market Report 2025

The metabolic syndrome market size has grown strongly in recent years. It will grow from $84.03 billion in 2024 to $90.6 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth during the historic period can be attributed to sedentary work environments, the expansion of nutraceuticals and functional foods, rising consumer demand for natural products, increasing clinical research and trials, and advancements in healthcare digitalization.

The metabolic syndrome market size is expected to see strong growth in the next few years. It will grow to $120.69 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth during the forecast period can be attributed to rising stress levels in daily life, increasing healthcare awareness, growing demand for advanced diagnostic tools, a higher number of diagnostic tests for metabolic conditions, and expanding healthcare insurance coverage. Key trends in the forecast period include advancements in medical technology, enhanced metabolic health monitoring, the integration of artificial intelligence, the adoption of digital health tools, and the development of smart ingestible pills.

The rising prevalence of lifestyle diseases is expected to drive growth in the metabolic testing market. Lifestyle diseases are health conditions primarily caused by unhealthy habits and behaviors rather than genetic or infectious factors. Common examples include obesity, cancer, type 2 diabetes, osteoporosis, and mental health disorders. The increasing incidence of these conditions is attributed to sedentary lifestyles, unhealthy diets, rising stress levels, and the widespread use of tobacco and alcohol. Metabolic syndrome plays a crucial role in worsening lifestyle diseases by promoting chronic inflammation, impaired metabolic functions, and heightened cardiovascular risks. For example, according to the National Health Service England, a UK-based government department, the number of individuals diagnosed with non-diabetic hyperglycemia (pre-diabetes) increased by 18% from 3,065,825 cases in 2022 to 3,615,330 cases in 2023. As a result, the growing prevalence of lifestyle diseases is fueling the expansion of the metabolic testing market.

Leading companies in the metabolic syndrome market are focusing on technological innovations, such as clinically supported probiotic solutions, to improve disease management, treatment, and prevention. Clinically supported probiotic solutions undergo rigorous clinical testing to validate their health benefits and safety. For instance, in October 2024, Probi USA, a US-based manufacturer of clinically proven biotics, launched "Metabolic Health," a probiotic product combining two strains that include Lactiplantibacillus plantarum 299v (LP299V) and Lacticaseibacillus paracasei 8700,2 (L. Paracasei 8700,2). LP299V supports cardiovascular health by improving cholesterol levels, inflammation, and blood vessel function, with over 230 publications and eight clinical trials backing its efficacy. L. Paracasei 8700,2, supported by over 30 publications, aids in blood pressure regulation, cholesterol management, and weight control.

In August 2023, Novo Nordisk A/S, a Denmark-based pharmaceutical company, acquired Inversago Pharma for an undisclosed amount. This acquisition strengthens Novo Nordisk’s clinical pipeline for obesity and related disorders by investigating Inversago's lead drug, INV-202, as a potential treatment for obesity and its associated complications. Inversago Pharma Inc. is a Canada-based clinical-stage biopharmaceutical company specializing in therapies for metabolic and fibrotic diseases.

Major players in the metabolic syndrome market are Novo Nordisk A/S, Sanofi S.A., Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck KGaA, Amgen Inc., AstraZeneca PLC, Adocia, Biocon Ltd., Bristol-Myers Squibb Company, Cipla Limited, Herbalife International of America Inc., Abbott Laboratories, Shaklee Corporation, Johnson & Johnson Private Limited, Medtronic plc, Apollo, WW International Inc., Jenny Craig, DSM, Takeda Pharmaceutical Company Limited, Pfizer, Inc., Novartis AG, F. Hoffmann-La Roche AG, Merck & Co. Inc.

North America was the largest region in the metabolic syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in metabolic syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metabolic syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Metabolic syndrome is a collection of risk factors that increase the likelihood of developing heart disease, stroke, and type 2 diabetes. It is commonly associated with poor lifestyle choices, including unhealthy eating habits, lack of physical activity, and obesity. Treatment primarily focuses on lifestyle modifications, such as dietary changes, regular exercise, and medications to manage specific risk factors.

The primary types of metabolic syndrome include type 1, type 2, and type 3 metabolic syndrome. Type 1 metabolic syndrome is a rare metabolic disorder, often linked to genetic or autoimmune factors, that contributes to insulin resistance, obesity, and other cardiovascular risks. Treatments target various risk factors, including obesity, insulin resistance, high blood pressure, and high cholesterol. Management options include medications, lifestyle modifications, and other therapeutic approaches. Treatment is administered through oral, parenteral, and other routes and is utilized by various end users, such as hospitals, home care, and specialty centers.

The metabolic syndrome market research report is one of a series of new reports that provides metabolic syndrome market statistics, including metabolic syndrome industry global market size, regional shares, competitors with a metabolic syndrome market share, detailed metabolic syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the metabolic syndrome industry. This metabolic syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The metabolic syndrome market consists of revenues earned by entities by providing services such medical management, nutrition counseling, physical activity programs, and insulin resistance management. The market value includes the value of related goods sold by the service provider or included within the service offering. The metabolic syndrome market also includes sales of risperidone, olanzapine, lithium and valproate, and fluoxetine or sertraline. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.